Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Taichi Takashina"'
Autor:
Daisuke Morinaga, Hajime Asahina, Shotaro Ito, Osamu Honjo, Hisashi Tanaka, Ryoichi Honda, Hiroshi Yokouchi, Keiichi Nakamura, Kei Takamura, Fumihiro Hommura, Yasutaka Kawai, Kenichiro Ito, Noriaki Sukoh, Keiki Yokoo, Ryo Morita, Toshiyuki Harada, Taichi Takashina, Tomohiro Goda, Hirotoshi Dosaka‐Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Cancer Medicine, Vol 12, Iss 10, Pp 11525-11541 (2023)
Abstract Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is uncl
Externí odkaz:
https://doaj.org/article/e841a5a350844541b0287c7aee9ab30b
Autor:
Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo, Yuka Fujita, Satoshi Oizumi, Ryo Morita, Yasuyuki Ikezawa, Hisashi Tanaka, Nozomu Kimura, Takaaki Sasaki, Noriaki Sukoh, Taichi Takashina, Toshiyuki Harada, Hirotoshi Dosaka-Akita, Hiroshi Isobe, the Hokkaido Lung Cancer Clinical Study Group Trial
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line th
Externí odkaz:
https://doaj.org/article/30fdf5599db64195b591b2c71f3f2250
Autor:
Munehiro Matsumoto, Kentaro Nagaoka, Masaru Suzuki, Satoshi Konno, Kei Takahashi, Taichi Takashina, Nobuhisa Ishiguro, Masaharu Nishimura
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-5 (2019)
Abstract Background Until now, the prevalence of macrolide-resistant Mycoplasma pneumoniae (MP) infection among adult patients has been low, and severe MP pneumonia due to a macrolide-resistant strain has seldom been reported. Here, we describe a rar
Externí odkaz:
https://doaj.org/article/fc5052246de44279b5a7c1082e487866
Autor:
Daisuke Morinaga, Jun Sakakibara, Megumi Furuta, Naofumi Shinagawa, Tomohiro Goda, Kento Wakabayashi, Emi Takakuwa, Taichi Takashina, Satoshi Konno
Publikováno v:
Haigan. 62:107-114
Autor:
Shigehiro Yagishita, Kageaki Watanabe, Satoshi Oizumi, Takamasa Hotta, Ryo Ko, Hajime Asahina, Yoshiro Nakahara, Hidenori Mizugaki, Sho Saeki, Toshiyuki Harada, Akinobu Hamada, Yuka Fujita, Taichi Takashina, Fumie Hosoda, Hiromi Nakamura, Hiroyuki Minemura, Keiichi Nakamura
Publikováno v:
European Journal of Cancer. 160:227-234
Purpose An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-ar
Autor:
Noriaki Sukoh, Osamu Honjo, Yasuyuki Ikezawa, Hisashi Tanaka, Atsushi Nakamura, Ryoichi Honda, Hiroshi Isobe, Gaku Yamamoto, Ryo Morita, Hajime Asahina, Kenichiro Ito, Hirotoshi Akita, Takaaki Sasaki, Nozomu Kimura, Hajime Kikuchi, Keiki Yokoo, Toshiyuki Sumi, Satoshi Oizumi, Toshiyuki Harada, Yuka Fujita, Taichi Takashina, Hirotoshi Dosaka-Akita, Fumihiro Hommura
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib as a first-line therapy for
Autor:
Masaru Suzuki, Nobuhisa Ishiguro, Kentaro Nagaoka, Satoshi Konno, Munehiro Matsumoto, Taichi Takashina, Kei Takahashi, Masaharu Nishimura
Publikováno v:
Kompass Neumología. 1:33-38
Antecedentes: Hasta ahora, la prevalencia de infecciones por Mycoplasma pneumoniae (MP) resistente a los macrólidos entre pacientes adultos ha sido baja, y los reportes de neumonía grave por MP debida a una cepa resistente a los macrólidos han sid
Autor:
Tomohiro Goda, Satoshi Oizumi, Kei Takamura, Yasutaka Kawai, Ryo Morita, Taichi Takashina, Hirotoshi Dosaka-Akita, Ryoichi Honda, Noriaki Sukoh, Toshiyuki Harada, Osamu Honjo, Shotaro Ito, Keiichi Nakamura, Keiki Yokoo, Hajime Asahina, Fumihiro Hommura, Kenichiro Ito, Hiroshi Isobe, Hisashi Tanaka
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 156
Objectives: Limited information is available on the appropriate treatment duration of immune checkpoint inhibitors (ICIs). We aimed to identify candidates who would benefit from ICI discontinuation after one year of treatment for metastatic non-small
Autor:
Kosuke Nakano, Kei Takamura, Hiroshi Yokouchi, Naoto Morikawa, Noriyuki Yamada, Osamu Honjo, Hajime Asahina, Takahiro Ogi, Satoshi Oizumi, Kenya Kanazawa, Taichi Takashina, Toshiyuki Harada, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Masao Harada, Masaharu Nishimura, Toraji Amano, Ryoichi Honda, Hiroshi Isobe
Publikováno v:
International Journal of Clinical Oncology. 23:1060-1069
Background: This study evaluated the efficacy and safety of switch maintenance erlotinib and bevacizumab after induction therapy with carboplatin/pemetrexed/bevacizumab for non-squamous non-small cell lung cancer (NSCLC) with wild-type EGFR. Methods:
Autor:
Toraji Amano, Hiroshi Tanaka, Hirotoshi Akita, Noriyuki Yamada, Toshiyuki Harada, Noriaki Sukoh, Yasutaka Kawai, Yoshihito Ohhara, Toshitaka Sato, Taichi Takashina, Osamu Honjo, Fumiko Sugaya, Fumihiro Hommura, Mamoru Kunisaki, Tetsuya Kojima, H. Ryoichi, Kei Takamura, Satoshi Oizumi, Yuka Fujita, Ichiro Kinoshita
Publikováno v:
Annals of Oncology. 30:v650-v651
Background Non-small cell lung cancer (NSCLC) is characterized by a high incidence of brain metastasis (BM) and the prognosis of NSCLC patients with BM is poor. Previous study demonstrated four prognostic factors, which were age, poor PS, presence of